Cutler Group LP Macrogenics Inc Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$15.91 - $21.88 $12,027 - $16,541	-756 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$19.74 - $28.7 $14,923 - $21,697	756 New	756 $15,000
Q1 2020 May 07, 2020	SELL	$4.28 - $12.11 $856 - $2,422	-200 Closed	0 $0
Q3 2019 Oct 28, 2019	SELL	$12.44 - $17.48 $7,464 - $10,488	-600 Reduced 75.0%	200 $2,000
Q4 2017 Jan 17, 2018	SELL	$16.19 - $20.3 $8,095 - $10,150	-500 Reduced 38.46%	800 $15,000
Q3 2017 Oct 17, 2017	BUY	$15.52 - $18.94 $20,176 - $24,622	1,300	1,300 $24,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.